Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
12 nov. 2024 16h05 HE
|
Artiva Biotherapeutics, Inc.
Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune...
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
11 nov. 2024 16h05 HE
|
Artiva Biotherapeutics, Inc.
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell...
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
22 oct. 2024 16h05 HE
|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
10 sept. 2024 16h05 HE
|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
29 août 2024 16h05 HE
|
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
18 juil. 2024 19h08 HE
|
Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering